GB824337A - Therapeutic compositions - Google Patents

Therapeutic compositions

Info

Publication number
GB824337A
GB824337A GB24071/56A GB2407156A GB824337A GB 824337 A GB824337 A GB 824337A GB 24071/56 A GB24071/56 A GB 24071/56A GB 2407156 A GB2407156 A GB 2407156A GB 824337 A GB824337 A GB 824337A
Authority
GB
United Kingdom
Prior art keywords
resin
cross
linked
cation exchange
sulphonic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB24071/56A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R J STRASENBURGH CO
Original Assignee
R J STRASENBURGH CO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BE550155D priority Critical patent/BE550155A/xx
Priority to BE525633D priority patent/BE525633A/xx
Application filed by R J STRASENBURGH CO filed Critical R J STRASENBURGH CO
Publication of GB824337A publication Critical patent/GB824337A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

An oral medicament having delayed release comprises a therapeutically effective amine absorbed (ionically bound) on a cross-linked sulphonic acid cation exchange resin, including phenol- and carboxylic-sulphonic acid cation exchange resins. Conventional excipients may be included in compositions to be administered as capsules, pills, powders, syrups or emulsions. The cross linkage of the resin is between 3 and 17% and the particle size is between 10 and 80 mesh. Sulphonated polymerizates of polyvinyl aryl compounds as in Specification 577,707, [Group IV], may be used, preferred resins being water-insoluble sulphonated polymers of a mixture comprising divinyl benzene and styrenes. The resin compounds are preferably substantially saturated with amine. In examples, a sulphonic acid cation exchange resin, 7-8% cross-linked made in accordance with Example (I) of Specification 577,707, but with 7.5 parts of divinyl benzene instead of 10 parts and a resin having a 4-5% cross-linked polyvinylstyrene nucleus are used.ALSO:An oral medicament having delayed release comprises a therapeutically effective amine absorbed (ionically bound) on a cross-linked sulphonic acid cation exchange resin, including phenol- and carboxylic-sulphonic acid cation exchange resins. Such amine means an organic compound containing a basic nitrogen group (other than a vitamin, amino acid or antibiotic), absorbable in the gastro-intestinal tract, stable in gastric juice and having an oral LD-50 value in rats of between 50 and 3000 mgms. per kgm. Conventional excipients may be included in compositions to be administered as capsules, pills, powders, syrups or emulsions. The cross linkage of the resin is between 3 and 17% and the particle size is between 10 and 80 mesh. Sulphonated polymerizates of polyvinyl aryl compounds as in Specification 577,707, [Group IV], may be used, preferred resins being water-insoluble sulphonated polymers of a mixture comprising divinyl benzene and styrenes. The resin compounds are preferably substantially saturated with amine. Amines include amphetamine, ephedrine, morpholine, preludin, phenyl-to-loxamine, purilamine, pyribenzamine, chlorothen, thonzylamine, chlor-trimetin, hexamethonium bromide, pathilon, morphine, codeine, dihydrocodeine, dihydrocodeinone, dihydrohydroxycodeinone, metopon, atropine, scopolamine, narcotine, papaverine, ethaverine, methyl atropine, methyl scopolamine, centrine, benadryl and other dialkylamino-ethoxyl antihistamines and chlorprophenpyridamine. Examples in which IR-20 is a sulphonic acid cation exchange resin, 7-8% cross-linked made in accordance with Example I of Specification 577,707 but with 7.5 parts of divinyl benzene instead of 10 parts; XE-100 is a resin having a 4-5% cross-linked polyvinylstyrene nucleus and XE-69 is a smaller particle size of IR-120, relate to absorption compounds of (1) IR-120: amphetamine, (2) IR-120: pyrilamine, (3) XE-100: pyrilamine, (4) XE-69: pyrilamine, (5) XE-69: pyribenzamine.
GB24071/56A 1955-08-08 1956-08-03 Therapeutic compositions Expired GB824337A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BE550155D BE550155A (en) 1956-08-03
BE525633D BE525633A (en) 1956-08-03

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US347942XA 1955-08-08 1955-08-08
US60256XA 1956-02-06 1956-02-06
US150356XA 1956-03-15 1956-03-15
US30556XA 1956-05-03 1956-05-03
US120756XA 1956-07-12 1956-07-12
US160756XA 1956-07-16 1956-07-16

Publications (1)

Publication Number Publication Date
GB824337A true GB824337A (en) 1959-11-25

Family

ID=27555438

Family Applications (1)

Application Number Title Priority Date Filing Date
GB24071/56A Expired GB824337A (en) 1955-08-08 1956-08-03 Therapeutic compositions

Country Status (6)

Country Link
BE (1) BE550150A (en)
CH (1) CH347942A (en)
DE (1) DE1045599B (en)
FR (1) FR1213407A (en)
GB (1) GB824337A (en)
MY (1) MY6300063A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2373288A1 (en) * 1976-11-26 1978-07-07 Pennwalt Corp LONG-RELEASE PHARMACEUTICAL PREPARATION
FR2589731A1 (en) * 1985-11-08 1987-05-15 Covex Sa PROCESS FOR THE PREPARATION OF (-) EBURNAMENINE-14- (15H) -ONE RESINATES

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1110819B (en) * 1958-11-14 1961-07-13 Frank W Horner Ltd Process for improving adsorbates of penicillin on anti-ion exchange resins
NL255047A (en) * 1959-08-21
DE1182390B (en) * 1960-12-27 1964-11-26 Dr Gustavo Damilano Process for reducing the rate of resorption of therapeutically active, soluble substances
JPS5762277A (en) * 1980-06-23 1982-04-15 Ciba Geigy Ag Manufacture of effect-enduring vincamine blend, obtained vincamine blend and medicine

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2373288A1 (en) * 1976-11-26 1978-07-07 Pennwalt Corp LONG-RELEASE PHARMACEUTICAL PREPARATION
FR2589731A1 (en) * 1985-11-08 1987-05-15 Covex Sa PROCESS FOR THE PREPARATION OF (-) EBURNAMENINE-14- (15H) -ONE RESINATES

Also Published As

Publication number Publication date
CH347942A (en) 1960-07-31
MY6300063A (en) 1963-12-31
DE1045599B (en) 1958-12-04
FR1213407A (en) 1960-03-31
BE550150A (en)

Similar Documents

Publication Publication Date Title
EP0368682B1 (en) Pharmaceutical ion exchange resin composition
CN1938004B (en) Tamper resistant dosage form comprising an adsorbent and an adverse agent
EP0185420B1 (en) Dihydrocodeine/ibuprofen pharmaceutical compositions and method
EP0847273B1 (en) Improved pharmaceutical ion exchange resin composition
AU676315B2 (en) Stabilized solid pharmaceutical preparation and method of producing the same
EP0557065A1 (en) Spheroid formulation
US4323577A (en) Aqueous solution of nitroglycerin
EP0435684A1 (en) Freeze-dried dosage forms and methods for preparing the same
KR890016968A (en) Pharmaceutical adsorbate
US4668684A (en) Combination of flupirtin and anticholinergic acting spasmolytic
GB824337A (en) Therapeutic compositions
KR920006908B1 (en) Process for preparing solid medicament preparation containing dihydropyridines
CN103372014B (en) A kind of energy Fast Stripping, stable Vardenafil hydrochloric acid oral solid formulation and preparation method thereof
GB2036048A (en) Polymer compounds, process for their preparation and arteriosclerosis treating agents containing them
FR561M (en)
CA1194798A (en) Pharmaceutical compositions
JPH08507751A (en) Benzoylecgonine derivatives, ecgonine derivatives, and ecgonidine derivatives as pharmaceuticals
EP1200088B1 (en) Paracetamol and drotaverine containing composition
CN104274414B (en) A kind of methyl naltrexone compound, oral tablet and preparation method thereof
US4781919A (en) Sustained release dosage form
US3096241A (en) Synergistic antihistamine mixture
CN100512807C (en) Pharmaceutical for preventing and curing acute gout, tumor and hepatic/pulmonary fibrosis and preparation method thereof
US3920806A (en) Growth promoting subcutaneous compositions
CN114073690B (en) Extraction-preventing pharmaceutical composition containing amino acid and preparation thereof
CN103768060B (en) Compound tablet of ibuprofen, pseudoephedrine hydrochloride and chlorpheniramine maleate